Canaccord analyst Mark Massaro is defending T2 Biosystems (NASDAQ: TTOO) by saying buy on weakness. Analyst comments: "Shares of T2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE